Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: SYNE2

Summary for SYNE2

Gene information	Gene symbol	SYNE2
	Ensembl ID	ENSG00000054654
	Entrez ID	23224
	Gene name	spectrin repeat containing nuclear envelope protein 2
	Synonyms	DKFZP434H2235\|KIAA1011\|Nesp2\|Nesprin-2\|NUA\|NUANCE\|SYNE-2
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: SYNE2

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.556037	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	-0.310344	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.39506	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.285676	3.48e-24
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.531701	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	0.361028	1.97e-31
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.345791	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	-0.434776	2.33e-17
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.470812	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.261369	8.49e-14
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	0.586198	8.20e-29
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.300478	4.16e-04
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	-0.321757	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	0.458697	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.363807	1.21e-33
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.481472	3.80e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.461938	1.80e-05
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	-0.299047	1.21e-10
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	Malignant cells	-0.380397	1.41e-21
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD4+ T cells	-0.485366	1.34e-07
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.308194	8.38e-06
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	-0.398405	0.00e+00

Top

Expression of SYNE2 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to SYNE2

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating SYNE2

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
SYNE2	hsa-miR-5581-3p	90.047	NM_015180
SYNE2	hsa-miR-9-3p	89.8634	NM_182913
SYNE2	hsa-miR-4764-5p	89.7024	NM_182913
SYNE2	hsa-miR-1264	88.6319	NM_182913
SYNE2	hsa-miR-4735-5p	86.9582	NM_182913
SYNE2	hsa-miR-4794	86.5336	NM_182913
SYNE2	hsa-miR-4682	85.9816	NM_182913
SYNE2	hsa-miR-6872-3p	85.6458	NM_015180
SYNE2	hsa-miR-323a-3p	85.3726	NM_182913
SYNE2	hsa-miR-548as-3p	84.7265	NM_015180
SYNE2	hsa-miR-548c-3p	84.2656	NM_015180
SYNE2	hsa-miR-664a-5p	84.1671	NM_182913
SYNE2	hsa-miR-5692c	83.4127	NM_182913
SYNE2	hsa-miR-5692b	83.4127	NM_182913
SYNE2	hsa-miR-12123	83.1199	NM_182913
SYNE2	hsa-miR-4692	81.7234	NM_182913
SYNE2	hsa-miR-4422	81.1499	NM_182913
SYNE2	hsa-miR-454-5p	80.0471	NM_182913

Page: 1

Top

Motifs and transcription factors (TFs) regulating SYNE2

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
SYNE2	transfac_pro__M04893	TAF1 (directAnnotation).
SYNE2	transfac_pro__M00430	E2F1 (directAnnotation).
SYNE2	transfac_pro__M01090	SMAD9 (inferredBy_Orthology).
SYNE2	hdpi__ZNF304	ZNF304 (directAnnotation).
SYNE2	metacluster_66.4	ARNT2; NR0B1; NR0B1; ZSCAN5A; ZSCAN5A (directAnnotation). ARNT2 (inferredBy_Orthology).
SYNE2	transfac_pro__M00938	E2F1 (directAnnotation).
SYNE2	transfac_pro__M06686	PRDM9 (directAnnotation).
SYNE2	kznf__KLF1_Barrera2016.2_PBM	KLF1 (directAnnotation).
SYNE2	transfac_pro__M05980	ZFP64 (directAnnotation).
SYNE2	metacluster_137.2	ATF3; BACH2; BATF; BATF; BATF; BATF; BATF3; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOS; FOSB; FOSB; FOSB; FOSB; FOSB; FOSL1; FOSL1; FOSL1; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; FOSL2; INSM2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUNB; JUNB; JUNB; JUNB; JUND; JUND; JUND; JUND; JUND; SMARCC1 (directAnnotation). ATF3; ATF3; BATF; FOS; FOSB; FOSL1; FOSL1; FOSL2; FOSL2; FOSL2; JUN; JUN; JUN; JUN; JUN; JUN; JUN; JUNB; JUND; JUND; JUND; JUND (inferredBy_Orthology).
SYNE2	taipale_tf_pairs__HOXB13_ETV1_RSCGGAARYNNTAAAN_CAP_repr	ETV1; HOXB13 (directAnnotation).
SYNE2	taipale_tf_pairs__ETV2_TEF_TTACGTNNNNNNNNNCCGGAANN_CAP_repr	ETV2; TEF (directAnnotation).
SYNE2	transfac_pro__M06239	ZNF844 (directAnnotation).
SYNE2	taipale_tf_pairs__ERF_MAX_RSCGGAANCACGTGN_CAP_repr	ERF; MAX (directAnnotation).
SYNE2	transfac_pro__M04856	BATF (directAnnotation).
SYNE2	transfac_pro__M06360	ZNF626 (directAnnotation).
SYNE2	metacluster_172.6	CHD2; E2F1 (directAnnotation).
SYNE2	kznf__ZNF846_Imbeault2017_RP_ChIP-seq	ZNF846 (directAnnotation).
SYNE2	transfac_pro__M05380	NR2E1 (inferredBy_Orthology).
SYNE2	taipale_tf_pairs__GCM2_DLX2_RTRCGGGNNNNNTAATTR_CAP_repr	DLX2; GCM2 (directAnnotation).
SYNE2	jaspar__MA1983.1	ZNF582 (directAnnotation).
SYNE2	taipale__YY2_DBD_NNCCGCCATNW_repr	YY2 (directAnnotation).
SYNE2	transfac_pro__M00803	E2F1; E2F3; E2F4; TFDP1 (directAnnotation).
SYNE2	hocomoco__ZBT14_HUMAN.H11MO.0.C	ZBTB14 (directAnnotation).
SYNE2	taipale_tf_pairs__ETV2_NHLH1_NCCGGAANNNNNNCAGCTGNN_CAP_repr	ETV2; NHLH1 (directAnnotation).
SYNE2	tfdimers__MD00483	ZBTB14 (directAnnotation).
SYNE2	transfac_pro__M06054	ZNF99 (directAnnotation).
SYNE2	transfac_pro__M06071	ZNF814 (directAnnotation).
SYNE2	taipale_cyt_meth__KLF3_NRCCGCAGCCCN_FL_meth_repr	KLF3 (directAnnotation).
SYNE2	metacluster_45.4	E2F2 (directAnnotation).
SYNE2	kznf__ZNF2_Imbeault2017_OM_RCADE	ZNF2 (directAnnotation).
SYNE2	transfac_pro__M04916	TAF1 (directAnnotation).
SYNE2	transfac_pro__M12355	ZNF549 (directAnnotation).
SYNE2	taipale_tf_pairs__FOXJ2_ELF1_RMAGAAAACCGAANN_CAP_repr	ELF1; FOXJ2 (directAnnotation).
SYNE2	tfdimers__MD00007	E2F1; IRF8 (directAnnotation).
SYNE2	hdpi__ZNF124	ZNF124 (directAnnotation).
SYNE2	metacluster_167.7	IRF8 (inferredBy_Orthology).
SYNE2	tfdimers__MD00527	IRF1; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF8; ZEB1 (directAnnotation).
SYNE2	metacluster_156.3	DBP; DBP; DBP; DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; TEF; TEF; TEF; TEF; TEF (directAnnotation). DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFILZ; NFILZ; TEF; TEF; TEF; TEF (inferredBy_Orthology).
SYNE2	transfac_public__M00040	ATF2 (directAnnotation).
SYNE2	hdpi__HTATIP2	HTATIP2 (directAnnotation).
SYNE2	hdpi__NRL	NRL (directAnnotation).
SYNE2	taipale_tf_pairs__E2F1_NHLH1_SGCGCCNNNNNNNNNNNNCAGCTGNN_CAP_repr	E2F1; NHLH1 (directAnnotation).
SYNE2	transfac_pro__M01199	TRIM28 (directAnnotation).
SYNE2	metacluster_9.11	GBX2 (directAnnotation).
SYNE2	metacluster_12.1	ZNF3 (directAnnotation).
SYNE2	kznf__ZNF33A_Imbeault2017_OM_RCADE	ZNF33A (directAnnotation).
SYNE2	taipale_cyt_meth__LHX9_CYAATTAR_eDBD	LHX9 (directAnnotation).
SYNE2	kznf__ZNF33A_Imbeault2017_RP_RCADE	ZNF33A (directAnnotation).
SYNE2	taipale_tf_pairs__FLI1_MAX_RSCGGAANCACGTGN_CAP	FLI1; MAX (directAnnotation).

Page: 1 2 3 4 5 6

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."